ARWR - Arrowhead Pharmaceuticals GAAP EPS of -$1.24 misses by $0.43 revenue of $3.55M misses by $26.09M
2024-02-06 16:24:31 ET
More on Arrowhead Pharmaceuticals
- Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy
- Arrowhead Pharmaceuticals: Transition To Commercialization
- Arrowhead Pharmaceuticals: Balance Sheet Concern Needs To Be Addressed
- Arrowhead Pharmaceuticals Q1 2024 Earnings Preview
- Arrowhead Pharmaceuticals Q4 2023 Earnings Preview